Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
5-Amino-1MQ
5-amino-1-methylquinolinium, NNMT inhibitor
A small molecule inhibitor of NNMT (nicotinamide N-methyltransferase), an enzyme that regulates fat cell metabolism and NAD+ availability. While technically a small molecule rather than a peptide, it is commonly grouped with peptide therapies in the metabolic health space due to its mechanism and delivery method.
A coenzyme found in all living cells that plays a central role in energy metabolism and cellular repair. NAD+ levels decline significantly with age. Injectable NAD+ and its precursors (NMN, NR) have become widely used in longevity and anti-aging protocols.
Inhibits NNMT, which normally converts NAD+ precursors into methylnicotinamide — a metabolic dead end. By blocking NNMT, 5-Amino-1MQ increases NAD+ availability in fat cells, activating SIRT1 and promoting fat oxidation. Reduces fat cell size and inhibits new fat cell formation (adipogenesis).
Serves as an electron carrier in cellular respiration (ATP production). Activates sirtuins (SIRT1-7), a family of proteins involved in DNA repair, inflammation regulation, and metabolic homeostasis. Also activates PARP enzymes involved in DNA damage repair.
- Fat loss and body composition
- Metabolic health improvement
- Obesity treatment (investigational)
- NAD+ pathway optimization
- Anti-aging and longevity protocols
- Energy and cognitive enhancement
- Addiction recovery support
- Athletic performance and recovery
- Metabolic health optimization
- Very limited human clinical data
- Long-term safety unknown
- Optimal dosing not established
- Potential off-target effects of NNMT inhibition not fully characterized
- Often sourced from gray-market vendors with variable quality
- IV infusions can cause flushing, nausea, chest tightness (usually transient)
- Oral precursors (NMN, NR) generally well-tolerated
- Long-term effects of supraphysiological dosing unknown
- Theoretical concern: NAD+ may support cancer cell metabolism
- Quality varies significantly across suppliers
Not FDA-approved and not on any compounding list. Available as a research chemical. Growing interest in the metabolic health community but human clinical trial data is extremely limited. Not a peptide in the strict sense — a small molecule — but commonly discussed alongside peptide therapies.
NAD+ itself is not FDA-approved as a drug. Injectable NAD+ is available through compounding pharmacies with a prescription. Oral precursors (NMN, NR) are sold as dietary supplements. Not on any FDA compounding category list — exists in a separate regulatory framework from the peptides affected by the 2026 reclassification.
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.